Guanidinopropionic Acid (GPA).
A creatine look-alike. Muscle takes it up through the creatine transporter, then holds a weaker instant energy buffer, which switches on the cell's energy sensor AMPK.
- Category
- Compound
What Guanidinopropionic Acid (GPA) is, and what it does.
- Does it work
- It suits researchers studying chronic cellular energy stress. It's the mechanistic opposite of creatine, so people chasing strength or power are looking at a different molecule.
- How much to take
- No human daily amount is on record. What exists is animal and cell work at laboratory exposures, so there's no maintenance band we can honestly give you.
- Time to feel it
- Nobody has measured this in people. In animal work the muscle energy changes take weeks of continuous exposure to appear.
- The first dose
- Nothing has been measured in humans on day one. The change it's known for is a shift in muscle chemistry that builds over weeks.
- With regular use
- Weeks of exposure lower muscle phosphocreatine and raise the AMP to ATP ratio, keeping AMPK switched on. That's an animal laboratory finding, not a human outcome.
- How well tolerated
- Human tolerability hasn't been characterised. Because it lowers the muscle energy buffer, anyone training hard or taking creatine should speak with a clinician first.
- How it feels
- No subjective experience has been documented. What it does reads out in muscle chemistry rather than in how a training session feels.
- The overlooked benefit
- It's one of the few ways to put a cell under sustained energy stress on purpose, which is how a good deal of AMPK biology was mapped in the first place.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- uptake through the creatine transporterAnimal study
- lowering of muscle phosphocreatineAnimal study
- AMP-activated protein kinase signallingAnimal study
- use as a laboratory model of chronic energy stressNarrative review
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
GPA enters muscle through the same transporter that creatine uses, and once inside it is phosphorylated to a phosphagen that regenerates ATP poorly. Taking the two together means each one reduces the other's cellular uptake, and the practical effect of GPA is to lower muscle phosphocreatine rather than raise it. The pair works against itself, so stacking them for a performance goal makes little sense.
Beta-alanine crosses membranes on beta-amino acid and taurine transporters, and guanidino analogues of the same backbone show overlapping affinity in transport studies. Where two structurally similar small molecules share a carrier, high intake of one lowers uptake of the other. This is inferred from transporter chemistry rather than measured in people taking both.
Guanidino compounds interact with the taurine transporter as well as the creatine transporter, so sustained GPA exposure can shift muscle taurine content. Any such effect is a marker of transport competition and not an outcome anyone has measured as performance or recovery. Read it as mechanistic.
GPA shares the three-carbon backbone of GABA with a guanidino group replacing the amine, and binding assays place it at inhibitory receptor sites. Whether that translates into any central effect at oral doses is untested. Nothing here supports pairing them, and the note exists so the structural overlap is on the record.
Nothing specific on file for Guanidinopropionic Acid (GPA). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Guanidinopropionic Acid (GPA) actually does.
Beta-guanidinopropionic acid mimics creatine closely enough that the same transporter carries it into cells, where the same enzyme converts it into a phosphate-storing form.
That phosphate-storing form hands off its phosphate to fuel cells much more slowly than creatine's own version does, so cells that build it up end up with a weaker quick-energy reserve.
Because it drains rather than builds the muscle's rapid energy reserve, GPA works in the opposite direction from creatine and isn't used to boost performance.
With ongoing exposure, GPA lowers the muscle's creatine-phosphate stores and shifts the cell's energy balance in a way that switches on an energy-stress sensor, which is why it's used as a lab tool to study chronic energy stress.
Where Guanidinopropionic Acid (GPA) comes from.
It is made in a lab, not extracted from anything. Chemists take beta-alanine and bolt on the same chemical group that makes creatine what it is, which is exactly why the body confuses the two.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
The three-carbon amino acid backbone that supplies the carboxylic acid and the amine to be guanylated.
The primary amine of beta-alanine is reacted with a guanylating reagent such as cyanamide or an S-methylisothiourea salt to install the guanidino group.
Crude product is recrystallised from water or aqueous alcohol to remove unreacted starting material and reagent residues.
Isolated as the zwitterionic free acid, assayed by HPLC, then either weighed as bulk powder or encapsulated.
The forms it comes in.
The essence, in one line each.
- The acute haemodynamic response to a single dose of beta-guanidinopropionic acid did not differ detectably from creatine or placebo in this trial, which is a failure to detect a difference rather than evidence that none exists.Randomised trial. Karamat et al., 2017 (British Journal of Clinical Pharmacology). PMID 28795416 ↗
- Published protocol setting out the randomised crossover design used to compare acute beta-guanidinopropionic acid against creatine and placebo in healthy men.Randomised trial. Karamat et al., 2015 (Trials). PMID 25888414 ↗
- Beta-guanidinopropionic acid feeding did not extend lifespan in Drosophila, and no survival benefit was detected at the doses tested.Animal study. Dorigatti et al., 2021 (Biochemistry and Biophysics Reports). PMID 34141906 ↗
- Guanidinopropionic acid appears in the altered gut metabolite profile reported in this rodent work, named only in passing rather than tested as an intervention.Animal study. Chen et al., 2024 (Brain, Behavior, and Immunity). PMID 38851306 ↗
- Guanidinopropionic acid is listed among gut-derived metabolites shifted by commensal colonisation, and was not administered or tested on its own.Animal study. Xu et al., 2026 (npj Biofilms and Microbiomes). PMID 42277050 ↗
These are the studies our verdict leans on, chosen from the 5 we read for Guanidinopropionic Acid (GPA). The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.